Here the inventors applied PDAC-derived CAF secretome on pancreatic cancer cells
and evaluated Sig-1R implication in stromal cues integration by PCC from signaling
transmission to biological outcomes, at the cellular and physiological level. They demonstrated that the loss of Sig-1R in epithelial cells inhibits stromal-induced tumor growth and metastatic process. Thus, the inventors demonstrate that Sig-1R is a key actor of the dialog between stromal and cancer cell compartments
The present invention relates to method for the treatment of pancreatic cancer in a
patient in need thereof comprising a therapeutically effective amount of a Sig-1R ligand